Cardium Therapeutics is a health sciences and regenerative medicine company, whose business model is designed to avoid reliance on a single technology platform or product type, creating multiple opportunities for success. The company seeks to bridge the gap between promising new technologies and product opportunities that are ready for commercialization. They are focused on the acquisition and development of new and innovative bio-medical product opportunities and businesses, targeting significant unmet medical needs that have a definable pathway to commercialization, partnering, and other forms of monetization.
Cardium's lead commercial product is Excellagen topical gel for wound care management. The company recently received FDA clearance for marketing and sale in the U.S., and they are currently exhibiting the product at the 2012 Spring Symposium on Advanced Wound Care (SAWC) in Atlanta, Georgia. Excellagen is designed to assist the healing of diabetic foot ulcers, pressure ulcers, and other dermal wounds. It's a highly-refined collagen-based topical gel, having a unique high molecular weight bovine Type I collagen formulation with a number of advantages for doctors. Market research indicates that physicians seek easy-to-use products to reduce preparation time and facilitate product application. Excellagen comes in ready-to-use pre-filled syringes, requiring no thawing or mixing, and only a thin layer needs to be applied over the wound area. In addition, it calls for application at only one or two week intervals. Excellagen represents a combination of effectiveness and ease of use unmatched in the marketplace.
Cardium's medical opportunities portfolio includes other promising candidates, and includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium® Health Sciences healthy lifestyle product platform. Their lead clinical development product candidate is Generx, a DNA-based angiogenic biologic that is intended for the treatment of patients with myocardial ischemia due to coronary artery disease. Cardium continues to actively evaluate new technologies and business opportunities.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net